Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 604 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... January 19, 2023 Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... January 11, 2024 Let’s Talk About Bubbles July 16, 2020 Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... January 7, 2021 Load more HOT NEWS FDA Proposes Changes to Mammography Standards to Inform Women About Breast... Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... K9 Police Officer In Berlin Beats Breast Cancer For Second Time ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ
